GeneCast Biotechnology Co., Ltd.

GeneCast Biotechnology Co., Ltd. was founded in November, 2014, and is based in HealthWork (Beijing) Industry Park. The company specializes in liquid biopsy, NGS, and bioinformatics, with a focus on advancing cancer treatment through precision cancer diagnostics and companion diagnostics. Genecast Biotechnology has developed a technology platform for cell-free DNA NGS-based tests for companion diagnostics, genetic profiling, prognosis, and monitoring for multiple solid tumors such as lung cancer, colorectal cancer, liver cancer, esophageal cancer, endometrial cancer, ovarian cancer, and cervical cancer. The company operates in the Biotechnology and Health Care sectors, with its headquarters in China. Its most recent funding round was a Series E investment on 26 October 2020, which saw participation from Taikang Asset, Matrix Partners China, China Structural Reform Fund, Hillhouse Investment, Jianxin Capital, China Capital Investment Group, and China Renaissance. With its innovative approach to cancer diagnostics and strong investor backing, GeneCast Biotechnology has positioned itself as a key player in the biotechnology industry.